TW202135861A - 藉由靶向igsf8以治療自體免疫疾病及癌症之組合物及方法 - Google Patents

藉由靶向igsf8以治療自體免疫疾病及癌症之組合物及方法 Download PDF

Info

Publication number
TW202135861A
TW202135861A TW109146016A TW109146016A TW202135861A TW 202135861 A TW202135861 A TW 202135861A TW 109146016 A TW109146016 A TW 109146016A TW 109146016 A TW109146016 A TW 109146016A TW 202135861 A TW202135861 A TW 202135861A
Authority
TW
Taiwan
Prior art keywords
igsf8
antibody
cancer
cells
cdr
Prior art date
Application number
TW109146016A
Other languages
English (en)
Chinese (zh)
Inventor
胡熙浩
肖騰飛
劉小樂
Original Assignee
中國大陸商上海尋百會生物科技有限公司
美商Gv20醫療責任有限公司
劉小樂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中國大陸商上海尋百會生物科技有限公司, 美商Gv20醫療責任有限公司, 劉小樂 filed Critical 中國大陸商上海尋百會生物科技有限公司
Publication of TW202135861A publication Critical patent/TW202135861A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW109146016A 2019-12-25 2020-12-24 藉由靶向igsf8以治療自體免疫疾病及癌症之組合物及方法 TW202135861A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019128294 2019-12-25
WOPCT/CN2019/128294 2019-12-25

Publications (1)

Publication Number Publication Date
TW202135861A true TW202135861A (zh) 2021-10-01

Family

ID=76575703

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109146016A TW202135861A (zh) 2019-12-25 2020-12-24 藉由靶向igsf8以治療自體免疫疾病及癌症之組合物及方法

Country Status (11)

Country Link
US (1) US20230056288A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081253A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023512151A (cg-RX-API-DMAC7.html)
KR (1) KR20220151161A (cg-RX-API-DMAC7.html)
CN (1) CN115551549A (cg-RX-API-DMAC7.html)
AU (1) AU2020413633A1 (cg-RX-API-DMAC7.html)
CA (1) CA3165908A1 (cg-RX-API-DMAC7.html)
IL (1) IL294280A (cg-RX-API-DMAC7.html)
MX (1) MX2022008061A (cg-RX-API-DMAC7.html)
TW (1) TW202135861A (cg-RX-API-DMAC7.html)
WO (1) WO2021129744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230077722A (ko) * 2020-08-10 2023-06-01 지브이20 테라퓨틱스 엘엘씨 Igsf8을 표적화하여 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604844A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2012021840A2 (en) * 2010-08-13 2012-02-16 Biovest International, Inc. Materials and methods for designing autologous idiotype vaccines and treatment of b-cell malignancies
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
WO2019084343A1 (en) * 2017-10-25 2019-05-02 The Administrators Of The Tulane Educational Fund PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF
US12545728B2 (en) * 2019-02-04 2026-02-10 Lonza Sales Ag Treatment of cancer metastasis by targeting exosome proteins

Also Published As

Publication number Publication date
EP4081253A4 (en) 2023-09-06
AU2020413633A1 (en) 2022-08-18
JP2023512151A (ja) 2023-03-24
MX2022008061A (es) 2022-10-27
CN115551549A (zh) 2022-12-30
KR20220151161A (ko) 2022-11-14
US20230056288A1 (en) 2023-02-23
CA3165908A1 (en) 2021-07-01
WO2021129744A1 (en) 2021-07-01
IL294280A (en) 2022-08-01
EP4081253A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
TWI725966B (zh) 癌症組合療法
JP2025108413A (ja) Psgl-1アンタゴニスト及びその使用
ES2899616T3 (es) Polipéptidos del dominio extracelular del CD80 para su uso en aumentar los linfocitos T de memoria central
TW201722985A (zh) Cd80胞外域多肽及其用於癌症治療
JP7719799B2 (ja) 抗ガレクチン-9抗体およびその使用
US12617860B2 (en) Anti-TNFR2 antibody and uses thereof
JP2025527535A (ja) 抗ccr8抗体およびその使用
WO2023281313A1 (en) Anti-tnfr2 antibody and uses thereof
JP2023537131A (ja) Igsf8を標的化することによる自己免疫疾患および癌を治療するための組成物および方法
US20230056288A1 (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40092079A (en) Anti-tnfr2 antibody and uses thereof